ABVC BioPharma announced that the Science Park Administration in Taiwan approved the plan for setting up a pilot Good Manufacturing Practice facility to produce Vitargus, a groundbreaking product in retinal detachment surgery, and to pursue the process development work for manufacturing optimization. The plan, proposed by ABVC‘s Taiwan affiliate and co-development partner, BioFirst Corporation, is to upgrade Vitargus’ manufacturing processes so that ultimately, it can handle the global market supply of Vitargus. The factory is located in Hsinchu Biomedical Science Park, Taiwan and BioFirst Corporation is targeting to complete the construction in 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABVC:
- ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
- ABVC BioPharma signs term sheet to earn licensing fees, royalties
- ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
- ABVC BioPharma to sell 500,000 shares at $3.50 in registered direct offering
- ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering